These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28167558)

  • 61. Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation.
    Altcheh J; Moscatelli G; Caruso M; Moroni S; Bisio M; Miranda MR; Monla C; Vaina M; Valdez M; Moran L; Ramirez T; Patiño OL; Riarte A; Gonzalez N; Fernandes J; Alves F; Ribeiro I; Garcia-Bournissen F
    PLoS Negl Trop Dis; 2023 May; 17(5):e0010850. PubMed ID: 37256863
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results.
    Richle RW; Raaflaub J
    Acta Trop; 1980 Sep; 37(3):257-61. PubMed ID: 6106364
    [No Abstract]   [Full Text] [Related]  

  • 63. The dog as model for chemotherapy of the Chagas' disease.
    Guedes PM; Veloso VM; Tafuri WL; Galvão LM; Carneiro CM; Lana Md; Chiari E; Ataide Soares K; Bahia MT
    Acta Trop; 2002 Oct; 84(1):9-17. PubMed ID: 12387906
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report.
    Alarcón de Noya B; Ruiz-Guevara R; Noya O; Castro J; Ossenkopp J; Díaz-Bello Z; Colmenares C; Suárez JA; Noya-Alarcón O; Naranjo L; Gutiérrez H; Quinci G; Torres J
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):319-325. PubMed ID: 28132566
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
    Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
    Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of essential oil of Syzygium aromaticum alone and in combination with benznidazole on murine oral infection with Trypanosoma cruzi IV.
    Zanusso Junior G; Massago M; Kian D; Toledo MJO
    Exp Parasitol; 2018 Feb; 185():92-97. PubMed ID: 29305891
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice.
    Dzul-Huchim VM; Ramirez-Sierra MJ; Martinez-Vega PP; Rosado-Vallado ME; Arana-Argaez VE; Ortega-Lopez J; Gusovsky F; Dumonteil E; Cruz-Chan JV; Hotez P; Bottazzi ME; Villanueva-Lizama LE
    PLoS Negl Trop Dis; 2022 Sep; 16(9):e0010258. PubMed ID: 36095001
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trypanosoma cruzi: alteration in the lymphoid compartments following interruption of infection by early acute benznidazole therapy in mice.
    Olivieri BP; de Souza AP; Cotta-de-Almeida V; de Castro SL; Araújo-Jorge T
    Exp Parasitol; 2006 Nov; 114(3):228-34. PubMed ID: 16620811
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
    Buckner FS; Bahia MT; Suryadevara PK; White KL; Shackleford DM; Chennamaneni NK; Hulverson MA; Laydbak JU; Chatelain E; Scandale I; Verlinde CL; Charman SA; Lepesheva GI; Gelb MH
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4914-21. PubMed ID: 22777048
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of Trypanosoma cruzi Nicaragua infection in mice.
    Rial MS; Arrúa EC; Natale MA; Bua J; Esteva MI; Prado NG; Laucella SA; Salomon CJ; Fichera LE
    J Antimicrob Chemother; 2020 Jul; 75(7):1906-1916. PubMed ID: 32274510
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the Western Brazilian Amazon.
    Teston APM; Fernandes NS; Abegg CP; de Abreu AP; Sarto MPM; Gomes ML; Toledo MJO
    Exp Parasitol; 2021 Sep; 228():108136. PubMed ID: 34280400
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.
    Egui A; Thomas MC; Fernández-Villegas A; Pérez-Antón E; Gómez I; Carrilero B; Del Pozo Á; Ceballos M; Andrés-León E; López-Ruz MÁ; Gainza E; Oquiñena E; Segovia M; López MC
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358581
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection.
    Davies C; Simonazzi A; Micheloud JF; Ragone PG; Cid AG; Negrette OS; Bermúdez JM; Parada LA
    J Parasitol; 2020 Jun; 106(3):323-333. PubMed ID: 32369594
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Benznidazole prevents endothelial damage in an experimental model of Chagas disease.
    Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD
    Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.
    Teston AP; Monteiro WM; Reis D; Bossolani GD; Gomes ML; de Araújo SM; Bahia MT; Barbosa MG; Toledo MJ
    Trop Med Int Health; 2013 Jan; 18(1):85-95. PubMed ID: 23130989
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi.
    Ciccarelli AB; Frank FM; Puente V; Malchiodi EL; Batlle A; Lombardo ME
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5315-20. PubMed ID: 22869565
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.